Michael LeBlanc

powered by
COS Expertise®
Fred Hutchinson Cancer Research Center
Full MemberAppointed: 2001
Fred Hutchinson Cancer Research Center
Public Health Sciences
Professional Headshot of Michael LeBlanc

Mailing Address

Fred Hutchinson Cancer Research Center
1100 Fairview Ave N
M3-C102
Seattle, Washington 98109
United States

Contact Information

Phone: (206) 667-6089
Fax: (206) 667-4408
mleblanc@fhcrc.org
http://mike-leblanc.fhcrc.org/

Qualifications

Ph.D., University of Washington, 1989.
M.Math., University of Waterloo, 1985.
B.S., Simon Fraser University, 1984.

Expertise and Research Interests

My research interests include the design and analysis of clinical trials, methods for exploratory analysis of survival data and adaptive non-parametric regression.

Most of my collaborative research focuses on the design, analysis and conduct of therapeutic clinical trials. I lead the statistical activities related to Phase II and Phase III clinical trials in lymphoma for the Southwest Oncology Group (SWOG). Recently I have been investigating design and analysis methods for targeting patient subgroups appropriate for both Phase II and Phase III clinical trials.

I am interested in the study of adaptive regression methods and their application to data arising from clinical trials. I have developed extensions or alternatives to tree-based methods to yield simple prognostic decision rules in collaboration with Dr. John Crowley (Cancer Research And Biostatistics, CRAB). One example of such methodology is a strategy for constructing prognostic groups based on recursive refinement or peeling algorithms which allow for calibration of the risk group in terms of outcome or fraction of patients in the group.

In addition, I have recently developed an algorithm called Extreme Regression for constructing either high- or low-risk outcome groups in collaboration with Dr. Charles Kooperberg and James Moon (FHCRC). The model leads to a simple inverse regression function which is represented as a Boolean decision rule similar to tree models. However, unlike trees, the new method can control the fraction of subjects identified by the rule.

Some of my other work has included methods for analyzing gene-expression and SNP data. A successful project was Logic Regression, a method which constructs predictors based on Boolean combinations of binary feature variables (led by Charles Kooperberg and originally part of Ingo Ruczinski's dissertation).

I am also currently working on methods that allow specification of genetic structure into the high dimensional regression problem.

Keywords

COS Keywords:

Cancer Or Carcinogenesis, Clinical Trial, Computer Graphics, Public Health, Statistics.

Additional Terms:

Clinical Trials, Survival Analysis, Tree-based Regression.

Previous Positions

1996-2001, Associate Member, Fred Hutchinson Cancer Research Center
1995-1996, Assistant Member, Fred Hutchinson Cancer Research Center
1990-1995, Assistant Professor, University of Toronto, Preventive Medicine and Biostatistics

Publications

  • Agrawal A, Moon J, Davis RK, Sakr WA, Giri SP, Valentino J, LeBlanc M, Truelson JM, Yoo GH, Ensley JF, Schuller DE (Oct 2007) Transoral carbon dioxide laser supraglottic laryngectomy and irradiation in stage I, II, and III squamous cell carcinoma of the supraglottic larynx: report of Southwest Oncology Group Phase 2 Trial S9709., Archives of otolaryngology--head & neck surgery, 133 (10), 1044-50 Abstract
  • Goldman B, LeBlanc M, Crowley J (2007) Interim Futility Analysis with Intermediate Endpoints, Clinical Trials, In Press
  • Roberts RA, Sabalos CM, LeBlanc ML, Martel RR, Frutiger YM, Botros IW, Rounseville MP, Seligmann BE, Miller TM, Grogan TM, Rimsza LM (2007) Quantitative nuclease protection assay in paraffin-embedded tissue replicates prognostic microarray gene expression in diffuse large-B-cell lymphoma, Laboratory Investigation, 87, 979-997
  • Kooperberg C, LeBlanc M (2007) Multivariate Nonparametric Regression, In: Ronghui X, Xiachun L (eds), High-Dimensional Data Analysis in Oncology, Springer, In Press (bookchapter)
  • Dai JY, Ruczinski I, LeBlanc M, Kooperberg C (2006) Imputation methods to improve inference in SNP associated studies., Genet Epidemiology, 30, 690-702
  • LeBlanc M, Moon J, Kooperberg C. (2006) Extreme regression., Biostatistics, 7 (1), 71-84
  • Adelstein DJ, LeBlanc M. (2006) Does induction chemotherapy have a role in the management of locoregionally advanced squamous cell head and neck cancer?, J Clin Oncol, 24 (17), 2624-2628
  • LeBlanc M, Rasmussen E, Crowley J: (2006) Constructing Prognostic Groups by Tree-based Partitioning and Peeling Methods., In: Crowley J, Ankerst DP (eds): Handbook of Statistics in Clinical Oncology, 2 Edition, New York, Marcel Dekker, 1734-1738 pages (bookchapter)
  • Rimsza LM, Roberts RA, Campo E, Grogan TM, Bea S, Salaverria I, Zettl A, Rosenwald A, Ott G, Muller-Hermelink HK, Delabie J, Fisher RI, Unger JM, LeBlanc M, al et. (2006) Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions., Blood, 107 (3), 1101-1107
  • Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, LeBlanc M, Fisher RI. (2006) Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group protocol S9911., J Clin Oncol, 24 (25), 4143-4149
  • Fan J, Su XG, Levine R, Nunn M, LeBlanc M (2006) Trees for correlated survival data by goodness of split, with applications to tooth prognosis, Journal of the American Statistical Association, 101 (475), 959-967
  • Schwartz DL, Ford EC, Rajendran J, Yueh B, Coltrera MD, Virgin J, Anzai Y, Haynor D, Lewellen B, Mattes D, Kinahan P, Meyer J, Phillips M, Leblanc M, Krohn K, Eary J, Laramore GE (Jun 2005) FDG-PET/CT-guided intensity modulated head and neck radiotherapy: a pilot investigation., Head & Neck, 27 (6), 478-87 Abstract
  • LeBlanc M, Moon J, Crowley J (Jun 2005) Adaptive risk group refinement., Biometrics, 61 (2), 370-8 Abstract
  • Unger JM, Thompson IM Jr, LeBlanc M, Crowley JJ, Goodman PJ, Ford LG, Coltman CA Jr (Apr 2005) Estimated impact of the Prostate Cancer Prevention Trial on population mortality., Cancer, 103 (7), 1375-80 Abstract
  • Schwartz DL, Ford EC, Rajendran J, Yueh B, Coltrera MD, Virgin J, Anzai Y, Haynor D, Lewellen B, Mattes D, Kinahan P, Meyer J, Phillips M, LeBlanc M, et al. (2005) FDG-PET/CT-guided intensity modulated head and neck radiotherapy: a pilot investigation., Head Neck, 27 (6), 478-487
  • Schwartz DL, Ford E, Rajendran J, Yueh B, Coltrera MD, Virgin J, Anzai Y, Haynor D, Lewellyn B, Mattes D, Meyer J, Phillips M, Leblanc M, Kinahan P, Krohn K, Eary J, Laramore GE (Jan 2005) FDG-PET/CT imaging for preradiotherapy staging of head-and-neck squamous cell carcinoma., International Journal of Radiation Oncology, Biology, Physics, 61 (1), 129-36 Abstract
  • 54. Nason M, Emerson S, LeBlanc M. (2004) CARTscans: a tool for visualizing complex models., J Comput Graph Stat, 13 (4), 807-825
  • Ruczinski I, Kooperberg C, LeBlanc ML (2004) Exploring interactions in high-dimensional genomic data: an overview of logic regression, with applications., Journal of Multivariate Analysis, 90, 178-195
  • Schwartz DL, Rajendran J, Yueh B, Coltrera MD, Leblanc M, Eary J, Krohn K (Dec 2004) FDG-PET prediction of head and neck squamous cell cancer outcomes., Archives of Otolaryngology--head & Neck Surgery, 130 (12), 1361-7 Abstract
  • Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, Fisher RI, Braziel RM, Rimsza LM, Grogan TM, Miller TP, LeBlanc M, Greiner TC, Weisenburger DD, Lynch JC, Vose J, Armitage JO, Smeland EB, Kvaloy S, Holte H, Delabie J, Connors JM, Lansdorp PM, Ouyang Q, Lister TA, Davies AJ, Norton AJ, Muller-Hermelink HK, Ott G, Campo E, Montserrat E, Wilson WH, Jaffe ES, Simon R, Yang L, Powell J, Zhao H, Goldschmidt N, Chiorazzi M, Staudt LM (Nov 2004) Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells., The New England Journal of Medicine, 351 (21), 2159-69 Abstract
  • Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, Au WY, Bellei M, Brice P, Caballero D, Coiffier B, Conde-Garcia E, Doyen C, Federico M, Fisher RI, Garcia-Conde JF, Guglielmi C, Hagenbeek A, Haioun C, LeBlanc M, Lister AT, Lopez-Guillermo A, McLaughlin P, Milpied N, Morel P, Mounier N, Proctor SJ, Rohatiner A, Smith P, Soubeyran P, Tilly H, Vitolo U, Zinzani PL, Zucca E, Montserrat E (Sep 2004) Follicular lymphoma international prognostic index., Blood, 104 (5), 1258-65 Abstract
  • Rimsza LM, Roberts RA, Miller TP, Unger JM, LeBlanc M, Braziel RM, Weisenberger DD, Chan WC, Muller-Hermelink HK, Jaffe ES, Gascoyne RD, Campo E, Fuchs DA, Spier CM, Fisher RI, Delabie J, Rosenwald A, Staudt LM, Grogan TM (Jun 2004) Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and, Blood, 103 (11), 4251-8 Abstract
  • Unger JM, LeBlanc M, Thompson IM, Coltman CA Jr (Jul-Aug 2004) The person-years saved model and other methodologies for assessing the population impact of cancer-prevention strategies., Urologic Oncology, 22 (4), 362-8 Abstract
  • Unger JM, LeBlanc M, Crowley JJ, Grossman HB, Natale RB, Wozniak AJ, Berenson JR, List AF, Peters WA 3rd, Flanigan RC, Macdonald JS, Al-Sarraf M, Thompson IM, Coltman CA Jr (Dec 2003) Estimating the impact of new clinical trial proven cancer therapy and cancer chemoprevention on population mortality: the Karnofsky Memorial lecture., Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology., 21 (23 Suppl), 246s-252s Abstract
  • Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne RD, Chan WC, Zhao T, Haioun C, Greiner TC, Weisenburger DD, Lynch JC, Vose J, Armitage JO, Smeland EB, Kvaloy S, Holte H, Delabie J, Campo E, Montserrat E, Lopez-Guillermo A, Ott G, Muller-Hermelink HK, Connors JM, Braziel R, Grogan TM, Fisher RI, Miller TP, LeBlanc M, Chiorazzi M, Zhao H, Yang L, Powell J, Wilson WH, Jaffe ES, Simon R, Klausner RD, Staudt LM (Sep 2003) Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma., The Journal of Experimental Medicine, 198 (6), 851-62 Abstract
  • Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, LeBlanc M, Gaynor ER, Rivkin SE, Fisher RI (Sep 2003) A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911., Blood, 102 (5), 1606-12 Abstract
  • Stiff PJ, Unger JM, Forman SJ, McCall AR, LeBlanc M, Nademanee AP, Bolwell BJ, Fisher RI, Southwest Oncology Group (Aug 2003) The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial., Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation., 9 (8), 529-39 Abstract
  • Blayney DW, LeBlanc ML, Grogan T, Gaynor ER, Chapman RA, Spiridonidis CH, Taylor SA, Bearman SI, Miller TP, Fisher RI, Southwest Oncology Group (Jul 2003) Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 93, Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology., 21 (13), 2466-73 Abstract
  • Ruczinski I, Kooperberg C, LeBlanc M (2003) Logic Regression, Journal of Computational and Graphical Statistics, 3 (12), 475-511
  • LeBlanc M, Kooperberg C, Grogan TM, Miller TP (Apr 2003) Directed indices for exploring gene expression data., Bioinformatics (oxford, England), 19 (6), 686-93 Abstract
  • Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E, Gascoyne RD, Grogan TM, Muller-Hermelink HK, Smeland EB, Chiorazzi M, Giltnane JM, Hurt EM, Zhao H, Averett L, Henrickson S, Yang L, Powell J, Wilson WH, Jaffe ES, Simon R, Klausner RD, Montserrat E, Bosch F, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Fisher RI, Miller TP, LeBlanc M, Ott G, Kvaloy S, Holte H, Delabie J, Staudt LM (Feb 2003) The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma., Cancer Cell, 3 (2), 185-97 Abstract
  • Abdolell M, LeBlanc M, Stephens D, Harrison RV (Nov 2002) Binary partitioning for continuous longitudinal data: categorizing a prognostic variable., Statistics in Medicine, 21 (22), 3395-409 Abstract
  • Kooperberg C, Sipione S, LeBlanc M, Strand AD, Cattaneo E, Olson JM (Sep 2002) Evaluating test statistics to select interesting genes in microarray experiments., Human Molecular Genetics, 11 (19), 2223-32 Abstract
  • Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, Lopez-Guillermo A, Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt LM, Lymphoma/Leukemia Molecular Profiling Project (Jun 2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma., The New England Journal of Medicine, 346 (25), 1937-47 Abstract
  • LeBlanc M, Jacobson J, Crowley J (Jun 2002) Partitioning and peeling for constructing prognostic groups., Statistical Methods in Medical Research, 11 (3), 247-74 Abstract
  • Press OW, LeBlanc M, Lichter AS, Grogan TM, Unger JM, Wasserman TH, Gaynor ER, Peterson BA, Miller TP, Fisher RI (Nov 2001) Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease., Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology., 19 (22), 4238-44 Abstract
  • Faraggi D, LeBlanc M, Crowley J (Oct 2001) Understanding neural networks using regression trees: an application to multiple myeloma survival data., Statistics in Medicine, 20 (19), 2965-76 Abstract
  • Gaynor ER, Unger JM, Miller TP, Grogan TM, White LA Jr, Mills GM, Balcerzak SP, Varterasian M, LeBlanc M, Fisher RI (Feb 2001) Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma: a Southwest Oncology Group Study., Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology., 19 (3), 750-5 Abstract
  • Kooperberg C, Ruczinski I, LeBlanc ML, Hsu L (2001) Sequence analysis using logic regression., Genetic Epidemiology, 21 Suppl 1, S626-31 Abstract
  • Taylor CW, LeBlanc M, Fisher RI, Moore DF Sr, Roach RW, Elias L, Miller TP (Oct 2000) Phase II evaluation of interleukin-4 in patients with non-Hodgkin's lymphoma: a Southwest Oncology Group trial., Anti-cancer Drugs, 11 (9), 695-700 Abstract
  • Fisher RI, Dana BW, LeBlanc M, Kjeldsberg C, Forman JD, Unger JM, Balcerzak SP, Gaynor ER, Roy V, Miller T (May 2000) Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809., Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology., 18 (10), 2010-6 Abstract
  • LeBlanc M, Crowley J (Oct 1999) Using the bootstrap for estimation in group sequential designs: an application to a clinical trial for nasopharyngeal cancer., Statistics in Medicine, 18 (19), 2635-44 Abstract
  • Liu PY, LeBlanc M, Desai M (Aug 1999) False positive rates of randomized phase II designs., Controlled Clinical Trials, 20 (4), 343-52 Abstract
  • LeBlanc M, Crowley J (Mar 1999) Adaptive regression splines in the Cox model., Biometrics, 55 (1), 204-13 Abstract
  • LeBlanc M, Tibshirani R, Monotone shrinkage trees, Journal of Computational and Graphical Statistics, 7(4), 417-433, 1999
  • Miller TP, Dahlberg S, Cassady JR, Adelstein DJ, Spier CM, Grogan TM, LeBlanc M, Carlin S, Chase E, Fisher RI, Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate and high-grade non-Hodgkin's lymphoma, New England Journal of Medicine, 339(10), 21-26, 1999
  • Al-Sarraf M, LeBlanc M, Giri PGS, et al, Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized intergroup study 0099, Journal of Clinical Oncology, 16(4), 1310-1317, 1999
  • Moore DF Jr, Brown TD, LeBlanc M, Dahlberg S, Miller TP, McClure S, Fisher RI (1999) Phase II trial of menogaril in non-Hodgkin's lymphomas: a Southwest Oncology Group trial., Investigational New Drugs, 17 (2), 169-72 Abstract
  • LeBlanc M, Tibshirani R. (1998) Monotone shrinkage trees., Journal of Computational and Graphical Statistics, 7 (4), 417-433
  • Miller TP, Dahlberg S, Cassady JR, Adelstein DJ, Spier CM, Grogan TM, LeBlanc M, Carlin S, Chase E, Fisher RI (Jul 1998) Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma., The New England Journal of Medicine, 339 (1), 21-6 Abstract
  • Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, Forastiere AA, Adams G, Sakr WA, Schuller DE, Ensley JF (Apr 1998) Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099., Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology., 16 (4), 1310-7 Abstract
  • Press OW, LeBlanc M, O'Rourke TJ, Gagnet S, Chapman RA, Balcerzak SP, Fisher RI (Feb 1998) Phase II trial of paclitaxel by 24-hour continuous infusion for relapsed non-Hodgkin's lymphomas: Southwest Oncology Group trial 9246., Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology., 16 (2), 574-8 Abstract
  • Stiff PJ, Dahlberg S, Forman SJ, McCall AR, Horning SJ, Nademanee AP, Blume KG, LeBlanc M, Fisher RI (Jan 1998) Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens--a Southwest Oncology Group trial., Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology., 16 (1), 48-55 Abstract
  • LeBlanc M. (1997) Restricted polynomial regression., Computational Statistics and Data Analysis, 24, :153-168
  • Miller TP, LeBlanc M, Grogan TM, Fisher RI (Oct 1997) Follicular lymphomas: do histologic subtypes predict outcome?, Hematology/oncology Clinics of North America, 11 (5), 893-900 Abstract
  • Kasenda M, Calzavara LM, Johnson I, LeBlanc M (Jul-Aug 1997) Correlates of condom use in the young adult population in Ontario., Canadian Journal of Public Health. Revue Canadienne De Sante Publique, 88 (4), 280-5 Abstract

Profile Details

Last Updated: 1/2/2008

COS Expertise ID #675794
Reference this profile directly: http://myprofile.cos.com/leblanca14